Jakafi 10 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FPRQ4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,231
Award facts
- Contract value 100% obligated
- $24,231.30 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $24.2K by the Defense Logistics Agency on September 25, 2025, for the supply of Jakafi 10 mg tablets (60-count packages). This firm fixed-price delivery order, with an ultimate completion date of September 26, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at approximately $500 million and extending through November 2026. The award carries no set-aside designation, demonstrating the contractor's competitive standing in the federal pharmaceutical procurement marketplace.
The delivery order supports DLA's mission to supply pharmaceutical products to Department of Defense healthcare facilities nationwide. Jakafi (ruxolitinib) is a prescription medication used to treat myeloproliferative neoplasms and other blood disorders, reflecting the critical role DMS Pharmaceutical Group plays in distributing specialized medications to military health systems. As a prime contractor under the SPE2DB program, DMS Pharmaceutical Group maintains a comprehensive portfolio of pharmaceutical products including branded and generic prescription drugs, biologics, and medical consumables, positioning the company as a significant supplier within the federal pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DB25FPRQ4?
SPE2DB25FPRQ4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 25, 2025.
How much is contract SPE2DB25FPRQ4 worth?
The government has obligated $24,231 on SPE2DB25FPRQ4.
Is contract SPE2DB25FPRQ4 an order under another contract?
Yes. SPE2DB25FPRQ4 is a delivery order under SPE2DB20D9127, an indefinite delivery contract.
Was contract SPE2DB25FPRQ4 competed?
The extent of competition for SPE2DB25FPRQ4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award